Iradimed Corp (NASDAQ:IRMD) VP Sells $41,060.00 in Stock

Iradimed Corp (NASDAQ:IRMD) VP Brent Johnson sold 2,000 shares of the firm’s stock in a transaction on Friday, June 28th. The shares were sold at an average price of $20.53, for a total value of $41,060.00. Following the sale, the vice president now directly owns 2,368 shares of the company’s stock, valued at approximately $48,615.04. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Brent Johnson also recently made the following trade(s):

  • On Monday, July 1st, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $20.46, for a total value of $20,460.00.
  • On Wednesday, July 3rd, Brent Johnson sold 3,000 shares of Iradimed stock. The stock was sold at an average price of $20.16, for a total value of $60,480.00.
  • On Wednesday, June 26th, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $20.34, for a total value of $20,340.00.
  • On Monday, June 24th, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $21.02, for a total value of $21,020.00.
  • On Friday, June 21st, Brent Johnson sold 2,000 shares of Iradimed stock. The stock was sold at an average price of $21.36, for a total value of $42,720.00.
  • On Wednesday, June 19th, Brent Johnson sold 3,000 shares of Iradimed stock. The stock was sold at an average price of $20.73, for a total value of $62,190.00.
  • On Friday, June 14th, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $20.00, for a total value of $20,000.00.
  • On Monday, June 10th, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $20.06, for a total value of $20,060.00.
  • On Wednesday, June 12th, Brent Johnson sold 3,000 shares of Iradimed stock. The stock was sold at an average price of $20.57, for a total value of $61,710.00.
  • On Friday, June 7th, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $20.00, for a total value of $20,000.00.

Iradimed stock traded down $0.11 during midday trading on Friday, reaching $18.28. The company’s stock had a trading volume of 77,662 shares, compared to its average volume of 91,719. Iradimed Corp has a 52 week low of $16.68 and a 52 week high of $38.78. The company has a current ratio of 9.48, a quick ratio of 8.63 and a debt-to-equity ratio of 0.06. The firm’s 50-day moving average is $19.92. The firm has a market cap of $203.95 million, a PE ratio of 42.51 and a beta of 1.64.

Iradimed (NASDAQ:IRMD) last announced its quarterly earnings results on Tuesday, April 30th. The medical equipment provider reported $0.11 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.11. Iradimed had a return on equity of 13.98% and a net margin of 23.00%. The firm had revenue of $8.44 million for the quarter, compared to analyst estimates of $8.38 million. Research analysts anticipate that Iradimed Corp will post 0.64 EPS for the current fiscal year.

Several hedge funds have recently made changes to their positions in the company. Navellier & Associates Inc boosted its stake in shares of Iradimed by 6.7% during the second quarter. Navellier & Associates Inc now owns 131,727 shares of the medical equipment provider’s stock valued at $2,694,000 after purchasing an additional 8,289 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Iradimed in the first quarter worth approximately $241,000. RK Capital Management LLC acquired a new position in shares of Iradimed in the first quarter worth approximately $3,648,000. Fiera Capital Corp acquired a new position in shares of Iradimed in the first quarter worth approximately $1,442,000. Finally, Acadian Asset Management LLC lifted its stake in shares of Iradimed by 10.9% in the first quarter. Acadian Asset Management LLC now owns 29,764 shares of the medical equipment provider’s stock worth $836,000 after acquiring an additional 2,920 shares during the period. 23.53% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages recently commented on IRMD. BidaskClub upgraded Zogenix from a “sell” rating to a “hold” rating in a research report on Thursday, May 9th. Zacks Investment Research upgraded HB Fuller from a “sell” rating to a “hold” rating in a research report on Wednesday, July 3rd. Finally, ValuEngine upgraded Zillow Group from a “hold” rating to a “buy” rating in a research report on Thursday, July 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $31.50.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.

Read More: Stock Symbols and CUSIP Explained

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.